Review on Teneligliptin: A novel antihyperglycemic agent

  • V. D. Gorde
  • Punit R. Rachh

Abstract

Diabetes mellitus relates a metabolic disorder of collective aetiology which is characterized by chronic hyperglycaemia caused due to disturbances of carbohydrate, lipid and protein metabolism due to impaired β cell function of pancreas or insulin resistance or both. Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of antidiabetic that show favorable results in improving glycemic control with a minimal risk of hypoglycemia and weight gain. Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus. Teneligliptin, characterized by a "J-shaped" structure formed by five consecutive rings which give unique binding characteristics, reflect in higher potency than other dipeptidyl peptidase 4 inhibitor. Teneligliptin is a novel antihyperglycemic agent with a preferable profile in terms of long-term efficacy and safety in patients with type 2 diabetes.


Keywords: Diabetes Mellitus, Dipeptidyl Peptidase 4 Inhibitor, Teneligliptin, Hypoglycemia,

Downloads

Download data is not yet available.

Author Biographies

V. D. Gorde

Research scholar, Department of pharmaceutical science, Bhagwant University, Ajmer, Rajasthan.

Punit R. Rachh

Rachh

Statistics
282 Views | 358 Downloads
How to Cite
1.
Gorde VD, Rachh PR. Review on Teneligliptin: A novel antihyperglycemic agent. JDDT [Internet]. 22Aug.2019 [cited 18Jun.2021];9(4-s):742-7. Available from: https://jddtonline.info/index.php/jddt/article/view/3275